Show simple item record

dc.contributor.authorCorcoran, A
dc.contributor.authorHickey, N
dc.contributor.authorBarry, M
dc.contributor.authorUsher, C
dc.contributor.authorMcCullagh, LM
dc.date.accessioned2017-10-04T13:48:35Z
dc.date.available2017-10-04T13:48:35Z
dc.date.issued2017-09
dc.identifier.urihttp://hdl.handle.net/10147/622575
dc.descriptionIn Ireland, Ivacaftor is reimbursed, on the High-Tech Drug Scheme, for the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation. The aim of this study was to analyse the utilisation and expenditure of Ivacaftor on this scheme in the 12 month period post-reimbursement. All patients who had received Ivacaftor (regardless of General Medical Services Scheme eligibility/ineligibility) were included. A total of 140 individuals (male=74; 53%) received Ivacaftor over the defined 12 month study period (from January 2015 to December 2015 inclusive). The cohort ranged in age from 6 years to 61 years. The mean age was 22 years; a positive skew in age distribution indicated that a greater number of the cohort were in the younger age groups. No statistically significant difference was detected in the mean ages of the male and female subgroups. Drug acquisition expenditure by the Health Services Executive on Ivacaftor over the 12 month study period was €29.81 million.en
dc.language.isoenen
dc.publisherIrish Medical Journalen
dc.subjectCYSTIC FIBROSISen
dc.subjectDRUG ADMINISTRATIONen
dc.subject.otherECONOMIC EVALUATIONen
dc.titleIvacaftor for Cystic Fibrosis: An Evaluation of Real World Utilisation and Expenditure in the Irish Healthcare Settingen
dc.typeArticleen
dc.identifier.journalIrish Medical Journalen


Files in this item

Thumbnail
Name:
art7.html
Size:
36.93Kb
Format:
HTML
Description:
Main Article

This item appears in the following Collection(s)

Show simple item record